Adverum Biotechnologies - ADVM Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $3.25
  • Forecasted Upside: 225.00 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.00
▲ +0.05 (5.26%)

This chart shows the closing price for ADVM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Adverum Biotechnologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADVM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADVM

Analyst Price Target is $3.25
▲ +225.00% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Adverum Biotechnologies in the last 3 months. The average price target is $3.25, with a high forecast of $4.00 and a low forecast of $2.50. The average price target represents a 225.00% upside from the last price of $1.00.

This chart shows the closing price for ADVM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 3 polled investment analysts is to hold stock in Adverum Biotechnologies. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 8 hold ratings
  • 0 sell ratings
4/12/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 0 sell ratings
7/11/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 8 hold ratings
  • 0 sell ratings
10/9/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 0 sell ratings
1/7/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 0 sell ratings
4/7/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
7/6/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/4/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/12/2022Chardan CapitalLower TargetNeutral$3.00 ➝ $2.50Low
7/7/2022Truist FinancialUpgradeHold ➝ Buy$3.00 ➝ $4.00N/A
4/11/2022Chardan CapitalReiterated RatingNeutralMedium
10/12/2021SVB LeerinkReiterated RatingHoldHigh
7/30/2021Royal Bank of CanadaReiterated RatingHold$6.00Medium
7/23/2021The Goldman Sachs GroupDowngradeBuy ➝ NeutralHigh
7/23/2021SVB LeerinkLower TargetMarket Perform$5.00 ➝ $2.00High
7/23/2021Chardan CapitalLower TargetNeutral$5.00 ➝ $3.00High
7/23/2021Cantor FitzgeraldDowngradeOverweight ➝ Neutral$23.00 ➝ $3.00High
7/1/2021Chardan CapitalReiterated RatingNeutralMedium
5/10/2021SVB LeerinkReiterated RatingOutperform ➝ Market Perform$5.00Low
5/5/2021Royal Bank of CanadaReiterated RatingOutperform ➝ Sector Perform$6.00Low
5/5/2021Truist FinancialReiterated RatingBuy ➝ Hold$30.00 ➝ $9.00N/A
5/5/2021Chardan CapitalReiterated RatingBuy ➝ Neutral$20.00 ➝ $5.00Low
5/3/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$5.00High
4/29/2021Lifesci CapitalDowngradeOutperform ➝ Market PerformHigh
4/29/2021Chardan CapitalDowngradeBuy ➝ Neutral$20.00 ➝ $5.00N/A
4/29/2021Truist FinancialDowngradeBuy ➝ Hold$30.00 ➝ $9.00N/A
4/29/2021SVB LeerinkLower TargetOutperform$21.00 ➝ $11.00N/A
4/29/2021Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$6.00N/A
3/2/2021Cantor FitzgeraldReiterated RatingOverweightHigh
12/15/2020UBS GroupInitiated CoverageNeutral$13.00High
11/12/2020Raymond JamesUpgradeUnderperform ➝ Market PerformLow
11/5/2020Lifesci CapitalReiterated RatingOutperformMedium
8/26/2020Raymond JamesReiterated RatingHoldHigh
8/11/2020SVB LeerinkBoost TargetOutperform$20.00 ➝ $21.00High
8/10/2020Piper SandlerBoost TargetOverweight$25.00 ➝ $30.00High
7/8/2020Cantor FitzgeraldBoost TargetOverweight$21.00 ➝ $36.00High
6/26/2020Raymond JamesDowngradeMarket Perform ➝ UnderperformHigh
6/16/2020Royal Bank of CanadaBoost TargetPositive ➝ Outperform$24.00 ➝ $30.00High
5/30/2020Chardan CapitalReiterated RatingBuyHigh
5/29/2020Piper SandlerBoost Target$20.00 ➝ $25.00High
5/12/2020Royal Bank of CanadaInitiated CoverageOutperform$24.00High
5/8/2020Chardan CapitalReiterated RatingBuy$20.00Low
5/5/2020SVB LeerinkBoost TargetOutperform$17.00 ➝ $20.00High
5/5/2020SunTrust BanksUpgradeHold ➝ Buy$13.00 ➝ $21.00High
4/28/2020The Goldman Sachs GroupInitiated CoverageBuy$17.00High
3/23/2020Chardan CapitalReiterated RatingBuy$20.00Low
3/16/2020SVB LeerinkInitiated CoverageOutperform$17.00High
2/11/2020SunTrust BanksBoost Target$13.00High
2/10/2020Chardan CapitalUpgradeNeutral ➝ Buy$10.00 ➝ $20.00High
2/9/2020Cantor FitzgeraldUpgradeNeutral ➝ Overweight$8.00 ➝ $21.00High
1/13/2020Piper SandlerBoost TargetOverweight$14.00 ➝ $20.00High
1/13/2020Piper Jaffray CompaniesBoost TargetOverweight$14.00 ➝ $20.00High
10/15/2019Chardan CapitalBoost TargetNeutral$6.00 ➝ $10.00High
9/17/2019Cantor FitzgeraldReiterated RatingNeutral$3.00 ➝ $8.00Low
9/13/2019SunTrust BanksLower TargetHold$12.00 ➝ $8.00High
9/13/2019Chardan CapitalLower TargetNeutral$10.00 ➝ $6.00High
8/19/2019Chardan CapitalReiterated RatingHold$10.00Medium
7/29/2019SunTrust BanksBoost TargetHold$12.00Low
7/9/2019CowenReiterated RatingBuyMedium
6/13/2019Raymond JamesInitiated CoverageMkt Perform ➝ Market PerformHigh
5/17/2019Piper Jaffray CompaniesBoost TargetOverweight$8.00 ➝ $12.00Low
5/16/2019CowenReiterated RatingBuyHigh
11/4/2018Cantor FitzgeraldDowngradeOverweight ➝ Hold$12.00 ➝ $4.00Low
11/2/2018Chardan CapitalReiterated RatingHold$4.50High
11/2/2018SunTrust BanksDowngradeBuy ➝ HoldHigh
11/2/2018Raymond JamesDowngradeOutperform ➝ Market PerformHigh
11/2/2018Piper Jaffray CompaniesSet TargetBuy$8.00High
10/3/2018Cantor FitzgeraldSet TargetBuy$12.00Medium
9/20/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$12.00High
8/30/2018SunTrust BanksInitiated CoverageBuy ➝ Buy$11.00High
8/9/2018Chardan CapitalReiterated RatingHold$8.00High
5/18/2018Piper Jaffray CompaniesInitiated CoverageBuy$12.00Medium
2/15/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$12.00Medium
12/19/2017Chardan CapitalReiterated RatingHoldLow
10/12/2017Raymond JamesInitiated CoverageOutperform ➝ Outperform$6.00N/A
(Data available from 10/4/2017 forward)

News Sentiment Rating

0.76 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
3/8/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/7/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/7/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/6/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/6/2022
  • 5 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/5/2022
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/4/2022
  • 6 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/4/2022

Current Sentiment

  • 6 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Adverum Biotechnologies logo
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $1.00
Low: $0.97
High: $1.06

50 Day Range

MA: $1.22
Low: $0.88
High: $1.61

52 Week Range

Now: $1.00
Low: $0.80
High: $2.52

Volume

552,274 shs

Average Volume

1,082,747 shs

Market Capitalization

$98.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.17

Frequently Asked Questions

What sell-side analysts currently cover shares of Adverum Biotechnologies?

The following Wall Street research analysts have issued reports on Adverum Biotechnologies in the last twelve months: Chardan Capital, StockNews.com, SVB Leerink LLC, and Truist Financial Co..
View the latest analyst ratings for ADVM.

What is the current price target for Adverum Biotechnologies?

2 Wall Street analysts have set twelve-month price targets for Adverum Biotechnologies in the last year. Their average twelve-month price target is $3.25, suggesting a possible upside of 225.0%. Truist Financial Co. has the highest price target set, predicting ADVM will reach $4.00 in the next twelve months. Chardan Capital has the lowest price target set, forecasting a price of $2.50 for Adverum Biotechnologies in the next year.
View the latest price targets for ADVM.

What is the current consensus analyst rating for Adverum Biotechnologies?

Adverum Biotechnologies currently has 2 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ADVM, but not buy more shares or sell existing shares.
View the latest ratings for ADVM.

What other companies compete with Adverum Biotechnologies?

How do I contact Adverum Biotechnologies' investor relations team?

Adverum Biotechnologies' physical mailing address is 800 Saginaw Drive, Redwood City CA, 94063. The biotechnology company's listed phone number is (650) 656-9323 and its investor relations email address is [email protected] The official website for Adverum Biotechnologies is www.adverum.com. Learn More about contacing Adverum Biotechnologies investor relations.